AbbVie is the 11th pharmaceutical maker to impose limits on 340B contract pharmacy.
Breaking News: AbbVie Becomes 11th Drug Maker to Restrict 340B Contract Pharmacy. Feds Appeal Rulings in Lilly, Novo Nordisk, and Sanofi Cases.
Biopharmaceutical company AbbVie—maker of the expensive and widely prescribed immunosuppressive medication Humira—today became the 11th drug manufacturer to announce conditions on 340B pricing when contract pharmacies dispense medicines to patients.
Starting Feb. 1, AbbVie will require hospitals to submit claims data on 340B contract pharmacy utilization to its vendor 340B ESP to be able to use bill to / ship to arrangements for AbbVie products with an unlimited number of contract pharmacies, the company said in a letter and FAQ today to covered entities. Grantee covered entities are exempt from the requirement. AbbVie will let hospitals that reject the requirement and that lack an in-house outpatient pharmacy designate a single contract pharmacy to receive and dispense orders of 340B-purchased AbbVie drugs.
AbbVie today announced conditions on 340B pricing when hospitals' contract pharmacies dispense medicines to patients. The federal government has filed notices of appeal in Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics' 340B contract pharmacy lawsuits.